Cor­rect­ed: Lil­ly upped its of­fer for Mor­phic by $11 per share, doc­u­ments show

In­dus­try in­sid­ers love to say biotechs are bought, not sold.

That ap­pears to be the case with au­toim­mune drug de­vel­op­er Mor­phic Ther­a­peu­tic, which is try­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER